KR20080059270A - Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물 - Google Patents

Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물 Download PDF

Info

Publication number
KR20080059270A
KR20080059270A KR1020087010363A KR20087010363A KR20080059270A KR 20080059270 A KR20080059270 A KR 20080059270A KR 1020087010363 A KR1020087010363 A KR 1020087010363A KR 20087010363 A KR20087010363 A KR 20087010363A KR 20080059270 A KR20080059270 A KR 20080059270A
Authority
KR
South Korea
Prior art keywords
agent
hcv
acid
carbon atoms
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020087010363A
Other languages
English (en)
Korean (ko)
Inventor
데이빗 렌위크 후크
Original Assignee
싸이넥시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이넥시스, 인크. filed Critical 싸이넥시스, 인크.
Publication of KR20080059270A publication Critical patent/KR20080059270A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020087010363A 2005-09-30 2006-10-02 Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물 Abandoned KR20080059270A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72267905P 2005-09-30 2005-09-30
US60/722,679 2005-09-30
US78754906P 2006-03-29 2006-03-29
US60/787,549 2006-03-29

Publications (1)

Publication Number Publication Date
KR20080059270A true KR20080059270A (ko) 2008-06-26

Family

ID=37906852

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087010363A Abandoned KR20080059270A (ko) 2005-09-30 2006-10-02 Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물

Country Status (13)

Country Link
US (1) US7754685B2 (https=)
EP (1) EP1933859A2 (https=)
JP (1) JP5517454B2 (https=)
KR (1) KR20080059270A (https=)
CN (1) CN105169369B (https=)
AU (1) AU2006299426B2 (https=)
BR (1) BRPI0616476A2 (https=)
CA (1) CA2623865A1 (https=)
IL (1) IL190478A0 (https=)
NZ (1) NZ567262A (https=)
RU (1) RU2440822C2 (https=)
WO (1) WO2007041632A2 (https=)
ZA (1) ZA200803493B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101068160B1 (ko) * 2008-12-30 2011-09-27 건국대학교 산학협력단 Ｃ형 간염 바이러스 ｒｎａ핵산 중합효소의 활성을 저해하는 신규 플라보놀 유도체

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
KR101309409B1 (ko) * 2004-10-01 2013-09-23 싸이넥시스, 인크. Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체
KR20080059270A (ko) 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
DE602006020152D1 (de) 2005-09-30 2011-03-31 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
DK2023918T3 (da) 2006-05-19 2011-04-26 Scynexis Inc Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
JP2009539292A (ja) * 2006-06-02 2009-11-12 ぺリション、クロード、アニー 活性電子の管理
BRPI0715714A2 (pt) * 2006-08-25 2014-03-11 Wyeth Corp Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
MX2011007194A (es) * 2009-01-07 2013-07-12 Scynexis Inc Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
EA201400138A1 (ru) 2011-07-15 2014-06-30 Басф Се Пестицидные способы применения замещенных 3-пиридилтиазольных соединений и производных для борьбы с животными-вредителями ii
RU2639388C1 (ru) * 2016-10-11 2017-12-21 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Композиция для терапии вирусного гепатита С
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
US12465629B2 (en) * 2020-04-15 2025-11-11 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022896A1 (fr) * 1993-03-31 1994-10-13 Tokyo Tanabe Company Limited Ameliorant de la cholestase
WO1995003056A1 (en) * 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
ATE209216T1 (de) * 1995-07-17 2001-12-15 Chem Ag C Cyclosporin-derivate mit anti-hiv-wirkung
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
PT1086124E (pt) 1998-06-12 2004-04-30 Chem Ag C Ciclosporinas novas
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
PT1091975E (pt) 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
PT982035E (pt) * 1998-08-18 2004-08-31 Panacea Biotec Ltd Composicao de ciclosporina compreendendo um veiculo hidrofilo
EP1162196A4 (en) 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
CN1498224A (zh) * 2000-07-21 2004-05-19 ���鹫˾ 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EA008380B1 (ru) * 2001-11-27 2007-04-27 Анадис Фармасьютикалз, Инк. 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
PL374781A1 (en) * 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US20050009877A1 (en) 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
MX2007000503A (es) 2004-07-14 2007-03-08 Novartis Ag Uso de una combinacion de ciclosporina e interferon pegilado para el tratamiento de hepatitis c(hcv).
US20060025267A1 (en) * 2004-07-29 2006-02-02 Mircea Gradu Differential with torque vectoring capabilities
KR101309409B1 (ko) * 2004-10-01 2013-09-23 싸이넥시스, 인크. Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체
BRPI0515494A (pt) * 2004-10-01 2008-07-29 Debiopharm Sa uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006071618A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compounds for flaviviridae treatment
AU2005322242B2 (en) 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
DE602006020152D1 (de) 2005-09-30 2011-03-31 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
KR20080059270A (ko) 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
DK2023918T3 (da) 2006-05-19 2011-04-26 Scynexis Inc Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101068160B1 (ko) * 2008-12-30 2011-09-27 건국대학교 산학협력단 Ｃ형 간염 바이러스 ｒｎａ핵산 중합효소의 활성을 저해하는 신규 플라보놀 유도체

Also Published As

Publication number Publication date
IL190478A0 (en) 2008-11-03
RU2440822C2 (ru) 2012-01-27
JP5517454B2 (ja) 2014-06-11
RU2008117157A (ru) 2009-11-10
AU2006299426A1 (en) 2007-04-12
CN105169369B (zh) 2019-10-18
CA2623865A1 (en) 2007-04-12
CN105169369A (zh) 2015-12-23
US7754685B2 (en) 2010-07-13
NZ567262A (en) 2011-12-22
US20070173440A1 (en) 2007-07-26
WO2007041632A2 (en) 2007-04-12
BRPI0616476A2 (pt) 2011-06-21
AU2006299426B2 (en) 2012-07-26
WO2007041632A3 (en) 2007-12-13
JP2009510129A (ja) 2009-03-12
ZA200803493B (en) 2009-12-30
EP1933859A2 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
JP5517454B2 (ja) Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
KR101309409B1 (ko) Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체
JP5322647B2 (ja) ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US8536114B2 (en) Macrocycles
US7576057B2 (en) Cyclic peptides
JP5820722B2 (ja) シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US7718767B2 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US20110144005A1 (en) Novel cyclic peptides
US20090306033A1 (en) Novel cyclic peptides
KR20120125610A (ko) 시클로스포린 유사체
CN101316606B (zh) 治疗和预防丙型肝炎感染的方法和药物组合物
HK1125953A (en) Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080429

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110929

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130501

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130501

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140402

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140103

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20140508

Appeal identifier: 2014101002022

Request date: 20140402

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140402

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140402

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130902

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20110929

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20140508

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20140507

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee